ADMA Biologics Stock Plummets on Short Seller Allegations

ADMA Biologics Shares Fall Sharply After Short Seller Report

ADMA Biologics Inc. (NASDAQ: ADMA) shares experienced a significant decline of over 9% on Tuesday following the release of a critical report by short-seller Culper Research. The report alleges that the biopharmaceutical company engaged in a "channel stuffing" scheme to artificially inflate its revenue growth figures.

Overview of the Allegations

Culper Research, which disclosed it holds a short position in ADMA, claims the company's reported growth is not organic but the result of forcing excess inventory onto its distributors through an undisclosed related party. The short-seller estimates that without this alleged scheme, ADMA's revenues would have declined by 3% in 2025, a stark contrast to the 20% growth the company reported.

The report points to several financial red flags, including a sharp increase in Days Sales Outstanding (DSO) from 43 to 113 days in 2025. It also highlights that two distributors, BioCare and CuraScript, accounted for 73% of revenues and 87% of year-end receivables, indicating significant concentration risk.

Market and Financial Impact

The immediate market reaction was a sharp sell-off of ADMA stock. Culper Research supports its claims by citing interviews with distributor employees who stated ADMA offered rebates and extended payment terms of up to 120 days to incentivize them to stock excess inventory of its product, ASCENIV.

Furthermore, the report presents third-party sales data showing a widening gap between sales to providers and ADMA's reported revenue. This discrepancy reportedly grew from $14 million in 2023 to $121 million in 2025. Culper also questioned the revenue figures based on the CEO's stated patient count, suggesting the reported numbers are mathematically inconsistent with patient usage estimates.

Summary

ADMA Biologics faces serious allegations that question the integrity of its reported financial growth. The market has reacted negatively to the claims of channel stuffing and revenue inflation. Investors will now await an official response from ADMA's management to address the specific evidence presented by Culper Research, which will be crucial for the stock's future performance.

FAQ

Q: Why did ADMA Biologics stock drop significantly?
A: The stock fell over 9% after short-seller Culper Research published a report alleging the company used a "channel stuffing" scheme to artificially inflate its revenue.

Q: What is the main accusation against ADMA Biologics?
A: The main accusation is that ADMA pushed excessive inventory to its distributors using incentives like extended payment terms, making its sales growth appear much stronger than it actually was.

Q: What key evidence did the short-seller report cite?
A: The report cited a major increase in Days Sales Outstanding (DSO), a large discrepancy between third-party sales data and reported revenue, and statements from distributor employees about excess inventory.

Source: Investing.com